High Expression of Myocyte Enhancer Factor 2C Predicts Poor Prognosis for Adult Acute Myeloid Leukaemia with Normal Karyotype
Xiaoyu Xu,Zhao Zeng,Li Huo,Hong Liu,Yu Yan,Ling Zhang,Jiannong Cen,Huiying Qiu,Xiaowen Tang,Chengcheng Fu,Yue Han,Miao,Zhengming Jin,Changgeng Ruan,Depei Wu,Suning Chen,Qinrong Wang,Litao Yan
DOI: https://doi.org/10.1111/bjh.16418
2020-01-01
British Journal of Haematology
Abstract:Acute myeloid leukaemia (AML) accounts for 80–90% of adult acute leukaemias (Freeman et al., 2008). Over the past decades, the prognosis has been improved with risk-adapted therapeutic strategies. Recently, altered gene expression was verified as a prognostic indicator in AML (Prada-Arismendy et al., 2017), and could used as a marker for minimal residual disease (MRD) to assess therapeutic efficacy and predict relapse (Moors et al., 2019). Identifying these markers is particularly important for AML with a normal karyotype (NK-AML) (Weber et al., 2016; Marjanovic et al., 2017). However, appropriate markers for MRD are still lacking in this very heterogeneous subgroup. The myocyte enhancer factor 2C gene (MEF2C), located at chromosome 5q14.3, encodes a transcription factor from the MCM1-agamous-deficiens-serum response factor family (Potthoff & Olson, 2007). As a selectively expressed transcription factor, MEF2C was originally identified to be an important muscle cell regulator (Di Giorgio et al., 2018). Ectopic expression of MEF2C was first identified in paediatric T-cell acute lymphoblastic leukaemia. In a mouse model, MEF2C can contribute to the transformation of MLL-AF9-induced committed progenitor cells to leukaemia (Schwieger et al., 2009). We analysed data from the leukaemia study ‘MILE’ and found that MEF2C expression in NK-AML was higher than in healthy bone marrow (BM) and that there was a heterogeneous pattern in NK-AML. Laszlo et al. reported that high MEF2C expression is associated with adverse-risk features and poor outcome in paediatric AML (Laszlo et al., 2015). However, there is no report about the prognostic significance of MEF2C expression levels in adult AML. Our previous data showed that MEF2C expression may have prognostic value for event-free survival (EFS) and overall survival (OS) in NK-AML (Yan et al., 2018). Here, we retrospectively analysed MEF2C expression in adult NK-AML patients to clarify its clinical significance. Furthermore, we preliminarily assessed the potential feasibility of MEF2C expression as a MRD biomarker for adult NK-AML in some cases. The study involved 178 adult NK-AML patients who were diagnosed and treated at the First Affiliated Hospital of Soochow University between January 2012 and December 2017. All patients met the following eligibility criteria: age ≥14 years old, NK confirmed by R-banding technology, and treatment with standard ‘3 + 7’ induction chemotherapy. AML patients harbouring specific fusion genes were excluded. Patients who achieved complete remission (CR) received consolidation chemotherapy with or without allogeneic stem cell transfer (SCT), depending on the availability of a matched related or unrelated donor. We used real-time PCR (Applied Biosystems, Waltham, MA, USA) to quantify MEF2C and WT1 transcript expression. The validation of the qPCR assay is shown in Figure S1. The expression value of one specific gene (GAPDH) was calculated by the relative quantitative method. Statistical analyses were performed using SPSS version 16.0 (IBM Corp., Armonk, NY, USA) (see in Data S1). Of 178 adult NK-AML patients, MEF2C messenger RNA (mRNA) expression varied >200-fold relative to GAPDH. The MEF2C transcript's expression was significantly higher in adult NK-AML patients than in 16 normal BM samples (P = 0·003, F = 9·447). MEF2C expression was not related to sex, age, white blood cell counts, haemoglobin levels, platelet counts, BM blast cell ratio or French–American–British (FAB) subtype. In molecular subgroups, we observed that the median expression of MEF2C was significantly lower in patients with nucleophosmin (NPM1) mutation (n = 50), as compared to patients with wild-type NPM1 (P = 0·012). We also found that patients with higher MEF2C expression were less likely to have accompanying NPM1 mutations. However, the median MEF2C expression was not significantly different between mutant and wild-type FLT3-ITD, CEBPA, DNMT3A, or KIT (Table 1). Of 122 NK-AML patients undergoing conventional induction chemotherapy, 92 patients achieved CR (75·4%) after a single course of chemotherapy. Patients with the highest MEF2C expression (4th quartile) were less likely to achieve CR after one course of chemotherapy (56·7% vs. 81·5%; χ2 = 7·537, P = 0·006). After a median 27 months of follow-up time (range 2–75), an inferior OS (P = 0·001, Fig 1A) and EFS (P = 0·023, Fig 1B) was observed. Significantly, multiple Cox regression analysis suggested that high MEF2C expression at de novo diagnosis was an independent marker for a poor prognosis of OS (HR 0·759, P = 0·047). Conversely, achieving CR after one course of induction chemotherapy and receiving haematopoietic SCT (HSCT) were two independent favourable prognostic factors for EFS and OS (Table SI). To evaluate the prognostic relevance of MEF2C expression levels during therapy, we dynamically monitored the MEF2C expression at different time points in a representative subgroup of 32 patients. In patients in CR, we found that MEF2C expression returned to the normal control levels, whereas MEF2C expression of seven relapsed patients was upregulated to the original and even higher levels again upon leukaemia recurrence (Fig 1C). Analysis of 58 patients receiving allogeneic HSCT showed that MEF2C expression levels were not significantly different between OS and EFS. This implies that HSCT may overcome the poor survival impact of higher MEF2C expression. However, further investigations with more patients are needed to verify this. We compared MEF2C expression with WT1 expression, which has been used for the detection of MRD. Our results suggested that MEF2C expression was in parallel with WT1 expression and followed a similar trend according to disease status. After consolidation therapy, increased MEF2C and WT1 expression was observed in one patient who was diagnosed with a clinical relapse 2·2 months later. Blinded samples from a validation test (122 AML and 16 healthy subjects) were used to validate the detection ability of MEF2C and WT1 for adult NK-AML. In that study, the receiver operating characteristic (ROC) curve of MEF2C expression was used to determine the values. With the ROC curve, the area under the curve of MEF2C and WT1 expression in NK-AML patients showed that MEF2C had a similar or even higher prognostic value than WT1 in adult NK-AML (0·918, 95% CI 0·870–0·965 vs. 0·826, 95% CI 0·746–0·907, Fig 1D). These results suggest that expression of the MEF2C gene transcript may be a feasible indicator for MRD detection in NK-AML. In the future, larger samples of patients are needed to verify this clinical application value. Overall, this is the first report demonstrating that high MEF2C expression in BM is an independent marker for poor OS in adult NK-AML patients. In adult NK-AML, MEF2C expression may contribute to better risk group stratification and choice of the appropriate treatment intensity. We thank all study participants, especially the patients and their families. We thank the staff of the Hematology Department of The First Affiliated Hospital of Soochow University and Jiangsu Institute of Hematology. This work was supported by the Natural Science Foundation of Jiangsu Province (grant no. BK20160342), the Innovation Capability Development Project of Jiangsu Province (grant no. BM2015004) and the Natural Science Foundation of China (81600116, 81570139, 81700140). LZY designed this study. LZY and QRW wrote the paper; XYX, ZZ, JNC provided and analysed RT-PCR data; LH, HL, YY, LZ collected samples and provided clinical data. HYQ, XWT, CCF, YH, MM, ZMJ provided patient care. SNC gave some advices for this study design and paper writing. CGR and DPW presented amendmental suggestion for the paper. LZY had full access to all data and carries final responsibility for submitting the paper for publication. All authors reviewed the draft of the submitted paper . The authors declare to have no potential conflicts of interest regarding the present work. Figure S1. (A) Amplification curves for mRNA in bone marrow cell samples obtained by using the SYBR Green assays for MEF2C. (B) Melt curve analysis of PCR products from using the SYBR Green assays for MEF2C. Table SI. Univariate and multivariate analyses of prognostic markers as predictors of overall survival and event-free survival. Data S1. Supplementary material. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.